Diligence memo · auto-generated · as of July 2, 2026
Ucb S.A.
Ucb S.A. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Ucb S.A. operates in Pharmaceuticals, based in SMYRNA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ucb S.A. has raised $788K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $788K on 2015-04-08.
Most recent recorded round closed around 2015-04-08.
Valuation (modeled)modeled
Provath models Ucb S.A. at approximately $37M (range $441K–$422M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.28× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 11.2 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 16% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 37% of those peers.
Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.